ArticleHeart rhythm O22026
Multicenter analysis of device-detected atrial fibrillation burden reduction after antiarrhythmic drug initiation.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence for Precision Antiarrhythmic Drug Therapy in Atrial Fibrillation: From Recurrence Prediction to Comparative Treatment Selection.Medicina (Kaunas, Lithuania) · 2026Review
- Atrial Fibrillation Burden: Assessment, Clinical Significance, and Therapeutic Implications.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are limited data on changes in atrial fibrillation (AF) burden after antiarrhythmic drug (AAD) initiation. Objective: The purpose of this study was to quantify AF burden after AAD initiation in patients with cardiac implantable electronic devices (CIEDs). Methods: We conducted a retrospective study of all patients with CIEDs from 2 academic hospitals with new AAD initiation between April 2018 and March 2022. AF burden was quantified in patients with CIEDs at up to 6 months pre- and 12 months post-AAD initiation. Results: There were 128 patients (mean age 73.6 ± 12.2 years; 78 [61%] male) included in the analysis. The mean time to first AF burden measurement post-AAD initiation was 5.0 ± 6.8 months, and 98 (76.6%) patients had >1 post-AAD AF burden measurement. There was a significant reduction in AF burden at both the first and final interrogations post-AAD initiation relative to pre-AAD AF burden {pre: 5.9% (interquartile range [IQR] 1.3%-29.7%); first post: 0.2% (IQR 0%-2.9%); final: 0.1% (IQR 0%-1.5%)}. The median reduction in AF burden was 90.5% (IQR 2.7%-100%) at the first interrogation and 97.4% (IQR 35.7%-100%) at the final interrogation. A significant reduction in AF burden was seen at both time points in subgroups prescribed amiodarone and nonamiodarone AADs as well as in those with high (≥90%) and low (≤20%) baseline AF burden ( Conclusion: There was a median reduction in AF burden of 97.4% (IQR 35.7%-100%) after AAD initiation in patients with CIEDs at the final interrogation. Results are consistent in subgroups of AAD type and baseline AF burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.